Jan 12 (Reuters) - Revvity said on Monday it expects its 2025 adjusted profit per share to exceed its forecast of $4.90 to $5, as the medical equipment maker benefits from renewed demand for contract research and diagnostics services.
The company's shares were up nearly 6% in extended trading.
Pharmaceutical companies have ramped up drug development in the U.S. amid evolving trade policies under President Donald Trump.
Revvity said it expects to report fourth-quarter revenue of around $772 million, above Wall Street estimates of $760.3 million, according to data compiled by LSEG.
It also expects annual revenue to grow 4% to $2.86 billion, above estimates of $2.84 billion.
The company will report its fourth-quarter and full year 2025 results on February 2.
(Reporting by Puyaan Singh in Bengaluru; Editing by Leroy Leo)
latest_posts
- 1
Home Remodel Administrations: Change Your Residing Space - 2Senegal president signs tough new anti-LGBT law doubling jail terms
- 3How color-changing, bacteria-infused spacesuits could help keep future astronauts safe from space radiation
- 4Nestlé recalls infant formula in 49 countries. See list.
- 5See the 'amazing' photos of Earth taken on historic Artemis II moon mission
- AI is making spacecraft propulsion more efficient – and could even lead to nuclear-powered rockets
- SpaceX rocket launches 140 satellites into orbit on Transporter-15, aces landing at sea (video)
- American tourists left stranded in the Caribbean following flight cancellations after airspace closed for Maduro operation
- Industrial zone damaged in Negev, falls in Sharon area after Iran fires missiles towards Israel
- Which Countries Would Suffer Most in a Global Energy Shutdown? This Study Has Answers
- Top notch DSLR Cameras for Photography Devotees
- Step by step instructions to Advance the Eco-friendliness of Your Kona SUV
- Getting ready for a Mechanized World: 10 Positions That computer based intelligence Could Dominate
- At least 7 dead as Israel renews attacks on Beirut and across Lebanon
